Advertisement

Caveat regarding CMS Merit-based Incentive Payment Systems incidental adrenal nodule measure

  • Joseph Holman
  • Roberto Salvatori
  • Elliot K. Fishman
  • Pamela T. Johnson
Perspective

Abstract

Current Medicare MIP measures encourage radiologists not to recommend follow-up for ≤ 1 cm adrenal nodules. However, a radiologist may be the first to discover a small, subclinical pheochromocytoma. As such, recognition of the enhancement pattern of pheochromocytoma is important to ensure detection and properly guide management, which begins with clinical and laboratory assessment for elevated catecholamines.

Keywords

Merit-based Incentive Payment Systems (MIPS) Incidental adrenal nodule Pheochromocytoma Computed tomography (CT) 

Notes

Compliance with ethical standards

Conflict of interest

Joseph Holman and Roberto Salvatori have nothing to disclosures. Elliot K. Fishman received grant funding from GE Healthcare and Siemens and Founder and stockholder of HipGraphics. Pamela T. Johnson is a Consultant to Oliver Wyman.

References

  1. 1.
    Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions– National Quality Strategy Domain: Effective Clinical Care https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_405_Claims.pdf. Accessed 5 Aug 5 2018
  2. 2.
    Mayo-Smith WW, Song JH, Boland GL, et al. (2017) Management of incidental adrenal masses: a white paper of the ACR incidental findings committee. J Am Coll Radiol. 14:1038–1044CrossRefGoogle Scholar
  3. 3.
    Oshmyansky AR, Mahammedi A, Dackiw A, et al. (2013) Serendipity in the diagnosis of pheochromocytoma. J Comput Assist Tomogr. 37(5):820–823CrossRefPubMedGoogle Scholar
  4. 4.
    Motta-Ramierz GA, Remer EM, Herts BR, Gill IS, Hamrahian AH (2005) Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR 185:684CrossRefGoogle Scholar
  5. 5.
    Kopetschke R, Slisko M, Kilisli A, et al. (2009) Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 161(2):355–361CrossRefPubMedGoogle Scholar
  6. 6.
    Goldstein RE, O’Neill JA, Holcomb GW, et al. (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg. 229:755CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Northcutt BG, Raman S, Long CM, et al. (2013) MDCT of adrenal masses: can dual-phase enhancement patterns be used to distinguish between adenoma and pheochromocytoma. AJR 201:834–839CrossRefPubMedGoogle Scholar
  8. 8.
    Northcutt BG, Trakhtenbroit MA, Gomez EN, Fishman EK, Johnson PT (2016) Adrenal adenoma and pheochromocytoma: comparison of multidetector CT venous enhancement levels and washout characteristics. J Comput Assist Tomogr. 40:194–200CrossRefPubMedGoogle Scholar
  9. 9.
    Stamm M, Abele JT (2014) Streamlining the imaging of clinically suspected pheochromocytoma: using urine metanephrines to decrease imaging costs. Can Assoc Radiol J. 65:372–378CrossRefPubMedGoogle Scholar
  10. 10.
    Sawka AM, Jaeschke R, Singh RJ, Young WF Jr (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 88:553–558CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Joseph Holman
    • 1
  • Roberto Salvatori
    • 2
  • Elliot K. Fishman
    • 1
  • Pamela T. Johnson
    • 1
  1. 1.Department of RadiologyJohns Hopkins HospitalBaltimoreUSA
  2. 2.Department of EndocrinologyJohns Hopkins HospitalBaltimoreUSA

Personalised recommendations